130 / 1631
Trial Endpoints
Primary
•
Global assessment of overall response of the combination of pembrolizumab plus
radiotherapy at 24 weeks
Secondary
•
Response after 12 weeks of pembrolizumab
•
Change (improvement) in response with combinational RT
•
Duration of response for the combination treatment/time to next treatment
•
Abscopal effect (measured by ‘shrinking’ of 5 pre-defined lesions which have
not been irradiated using a 5 point score).
•
Safety
•
Progression-Free & Overall survival